Fig. 11: Schematic model of the effect of BBR on AD-related target pathway.
From: Network pharmacology study on the mechanism of berberine in Alzheimer’s disease model
BBR reduced APP level and blocked amyloid plaque formation. BBR also promoted PPARG-mediated repression of the NF-κB pathway and inhibited inflammatory response.
